Τίτλος:
A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Purpose: Our goal was to examine a panel of 11 biochemical variables, measured in cytosolic extracts of ovarian tissues (normal, benign, and malignant) by quantitative ELISAs for their ability to diagnose, prognose, and predict response to chemotherapy of ovarian cancer patients. Experimental Design: Eleven proteins were measured (9 kallikreins, B7-H4, and CA125) in cytosolic extracts of 259 ovarian tumor tissues, 50 tissues from benign conditions, 35 normal tissues, and 44 tissues from nonovarian tumors that metastasized to the ovary. Odds ratios and hazard ratios and their 95% confidence interval were calculated. Time-dependent receiver operating characteristic curves for censored survival datawere used to evaluate the performance of the biomarkers. Resampling was used to validate the performance. Results: Most biomarkers effectively separated cancer from noncancer groups. A composite marker provided an area under the curve of 0.97 (95% confidence interval, 0.95-0.99) for discriminating normal and cancer groups. Univariately, hK5 and hK6 were positively associated with progression. After adjusting for clinical variables inmultivariate analysis, both hK10 and hK11 significantly predicted time to progression. Increasing levels of hK13 were associated with chemotherapy response, and the predictive power of hK13 to chemotherapy response was improved by a panel of five biomarkers. Conclusions: The evidence shows that a group of kallikreins and multiparametric combinations with other biomarkers and clinical variables can significantly assist with ovarian cancer classification, prognosis, and response to platinum-based chemotherapy. In particular, we developed a multiparametric strategy for predicting ovarian cancer response to chemotherapy, comprising several biomarkers and clinical features. ©2007 American Association for Cancer Research.
Συγγραφείς:
Zheng, Y.
Katsaros, D.
Shan, S.J.C.
De La Longrais, I.R.
Porpiglia, M.
Scorilas, A.
Kim, N.W.
Wolfert, R.L.
Simon, I.
Li, L.
Feng, Z.
Diamandis, E.P.
Περιοδικό:
Clinical Cancer Research
Λέξεις-κλειδιά:
B7 antigen; b7 h4 protein; CA 125 antigen; carboplatin; cisplatin; cyclophosphamide; doxorubicin; epirubicin; kallikrein; methotrexate; paclitaxel; protein hK10; protein hK11; protein hK13; protein hK14; protein hK4; protein hK5; protein hK6; protein hK7; protein hK8; unclassified drug, adult; aged; article; benign tumor; cancer combination chemotherapy; cancer diagnosis; cancer growth; cancer patient; confidence interval; controlled study; cytosol; enzyme linked immunosorbent assay; female; human; human tissue; major clinical study; ovary cancer; ovary tumor; priority journal; prognosis; receiver operating characteristic; univariate analysis, Adult; Aged; Aged, 80 and over; Antigens, CD80; CA-125 Antigen; Cytosol; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kallikreins; Middle Aged; Ovarian Neoplasms; Prognosis; Tumor Markers, Biological
DOI:
10.1158/1078-0432.CCR-07-1409
